CATALYST PHARMACEUTICALS, INC. 4

Molly Harper’s common stock, stock options, and RSUs in Catalyst Pharmaceuticals, Inc. were cashed out and cancelled at the $31.50 per share merger price in connection with the Angelini Pharma acquisition.

On July 15, 2026, in connection with the acquisition of Catalyst Pharmaceuticals, Inc. by Angelini Pharma S.p.A. at $31.50 per share, reporting person Molly Harper disposed of all her equity-based awards in a change‑of‑control cleanup: 3,694 shares of common stock were converted into cash at $31.50 per share, and multiple tranches of fully vested stock options (exercise prices ranging from $5.78 to $22.77) and restricted stock units were cancelled and converted into the right to receive cash equal to the merger consideration spread, with no remaining equity ownership reported after the transaction. This represents a non‑open‑market, merger‑driven cash‑out of her equity position rather than discretionary trading in the public market.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000177

Alert Tier

6